Drug Trial Radar · NCT06700720
YN001-004 in Patients With Coronary Atherosclerosis in Australia
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Feb 25, 2026
Primary completion
Jul 22, 2026
Study completion Jul 22, 2026
Sponsor
- Lead sponsor
- Beijing Inno Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
Conditions
- Coronary Artery Disease
- Coronary Atherosclerotic Disease
Interventions
Dose 1 YN001Drug
Dose 1 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Dose 2 YN001Drug
Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
EvolocumabDrug
Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in coronary plaque characteristics (volume and composition)Time frame: From baseline to Week 13
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
John Flynn Private Hospital
Tugun, Australia
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Albury Wodonga Private Hospital
Albury, New South Wales, Australia
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia
Altona Clinical Research
Melbourne, Victoria, Australia
Peninsula Heart Centre
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.